-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Eli Lilly announced that its new crown neutralizing antibody bebtelovimab has been granted Emergency Use Authorization (EUA) by the FDA for the treatment of patients with mild to moderate new coronary pneumonia
Bebtelovimab, a broad-spectrum neutralizing antibody introduced by Eli Lilly from Abcellera, has potent neutralizing activity against all currently known mutant strains, including the "Omicron" strain
The authorization is based on data from a Phase II clinical BLAZE-4 trial (NCT04634409)
Not long ago, Eli Lilly had signed an order with the U.